The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials
- D. G. Bostwick*
- , H. B. Burke
- , T. M. Wheeler
- , L. W.K. Chung
- , R. Bookstein
- , T. G. Pretlow
- , R. B. Nagle
- , R. Montironi
- , M. M. Lieber
- , R. W. Veltri
- , W. E. Grizzle
- , D. J. Grignon
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
43
Scopus
citations